Needham Reiterates Buy Rating on Taysha Gene Therapies, Inc.
Needham maintains its buy rating on Taysha with a $12 target, as TSHA trades at $6.53, a 72.91% upside from the current price.
Key Points
- Needham reiterated its buy rating on Taysha Gene Therapies with a $12 price target on June 22, 2026.
- Needham's $12 price target implies 72.91% upside from Taysha Gene Therapies, Inc.'s ($TSHA) current $6.94 share price.
- Shares of TSHA on NasdaqGS traded at $6.53 on Tuesday, with a market cap of $1.84 billion.
- Insiders recently bought shares, and several funds adjusted their holdings in Taysha.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Needham reiterated its buy rating on Taysha Gene Therapies, Inc. (NasdaqGS: TSHA) on June 22, 2026, setting a price target of $12. This reflects continued confidence in the company, as shares traded around $6.53 on Tuesday.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Taysha Gene Therapies
Several institutional investors have been adjusting their stakes in Taysha. RA Capital Management, L.P. held steady with 23.56 million shares valued at about $105.3 million. Goldman Sachs Group Inc. increased its holdings by 8,676,906 shares, bringing its total to 22.37 million shares worth approximately $99.99 million, a 63.4% rise. Meanwhile, BlackRock, Inc. trimmed its position by 277,521 shares, ending with 18.37 million shares valued at $82.09 million, a 1.5% decrease.
Taysha Gene Therapies, Inc. Stock Up 20.3%
Shares of Taysha Gene Therapies traded near $6.53 on Tuesday. The company has a market capitalization of approximately $1.84 billion. It is currently not profitable, with a forward P/E ratio of -14.51. The stock's beta is 1.177, indicating moderate volatility. Over the past year, the stock has ranged from $2.25 to $7.30. Its 50-day moving average is $5.96, and the 200-day moving average is $4.88. Taysha maintains a strong liquidity position with a current ratio of 14.04 and a quick ratio of 13.76, while its debt-to-equity ratio stands at 32.34.
$TSHA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Taysha Gene Therapies reported revenue of $7.47 million, with a net margin of 0.0% and a return on equity of -97.28%. The company is expected to announce its next earnings on August 12, 2026.
Insider Buying and Selling at Taysha Gene Therapies, Inc.
Recent insider activity at Taysha Gene Therapies included purchases by several insiders. On June 1, 2026, John Stalfort III, Alison Long, and Laura Sepp-Lorenzino each acquired 42,671 shares, and Phillip Donenberg bought 21,335 shares. These transactions were not executed under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 22, 2026, Needham maintained its buy rating on Taysha Gene Therapies with a $12 price target. Canaccord Genuity also kept its buy rating, setting a target of $17 on April 6, 2026. The consensus among analysts is a strong buy, with a mean price target of $12.23 based on 13 analyst opinions.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., based in Dallas, Texas, is a biotechnology company focusing on developing gene therapies for severe genetic diseases of the central nervous system. The company is working on treatments for conditions such as giant axonal neuropathy and Rett syndrome. Led by CEO Sean P. Nolan, Taysha collaborates with The University of Texas Southwestern Medical Center to advance its research.
Bottom Line
Needham's reiterated buy rating and $12 target for Taysha Gene Therapies reflect ongoing optimism about the company's potential. Investors closely watch these analyst updates for insights into the company's prospects. As a reminder, these ratings are based on past data and may not represent current conditions.
Get Taysha Gene Therapies, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TSHA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.